Alcon's Latest Breakthrough Surgical Technology, Unity VCS, receives Health Canada approval
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708893871/en/
UNITY® Vitreoretinal Cataract System (VCS)
'Today marks an important day for Canadian ophthalmologists as we introduce the next generation of equipment solutions in cataract and vitreoretinal surgery, and we are grateful to those who helped us reach this milestone,' said Franck Leveiller, Head of Global R&D and Chief Scientific Officer, Alcon. 'We have a long legacy of engaging our customers throughout the research and development process to design bold innovations in ophthalmology. This approval is a significant milestone in delivering meaningful impact for Canadian Eye Care Professionals and patients.'
Unity VCS is Alcon's most advanced vitreoretinal and cataract surgical innovations combined together in one integrated platform. Unity VCS is designed to deliver enhanced workflow efficiencies over Alcon's current leading systems, CONSTELLATION ® Vision System for vitreoretinal and combined procedures, and CENTURION ® Vision System with ACTIVE SENTRY ® for cataract surgery.
"The first time I used Unity VCS in a wet lab environment, I had a real 'wow' reaction," said Dr. Rosa Braga-Mele, ophthalmologist and chair of Alcon's North America Cataract Core Advisory Board. "This is a proud moment to see the world-class innovation from Alcon receive approval in Canada. I'm particularly excited about the stability of the fluidics and cutting efficiency of the platform, which is quite remarkable and will create considerable surgical efficiencies."
Unity VCS leverages a novel phacoemulsification modality to deliver up to two times faster nucleus removal ^ with 40% less energy * into the eye 1, and a first-of-its-kind phaco handpiece that estimates temperature at the incision site 3. In vitreoretinal advancements, the new technology offers cutting speeds of up to 30,000 cuts per minute, the world's fastest vitrectomy probe #,2,3. The platform offers surgical stability and efficiency with a unique proprietary fluidics system 3.
"As a global market leader in cataract and retina surgical products 4,5,6, Alcon recognizes that the increasing demand for these procedures 7,8,9 necessitates enhanced workflow efficiencies and excellent patient outcomes," said Jeroen Bastemeijer, General Manager, Alcon Canada. "Unity VCS builds on Alcon's expertise in surgical equipment with pioneering innovations for vitreoretinal and cataract surgery—driving advancements from cutting speeds to fluidics management, to ergonomics and workflow. We are thrilled to bring this latest breakthrough technology, Unity VCS, to Canadian clinics in 2026."
Alcon has tested Unity VCS during investigational advisory wet lab sessions with more than 200 highly experienced surgeons from 30+ countries. Commercial launch of Unity VCS is expected in early 2026.
Unity VCS is the latest innovation from the Alcon Vision Suite—a portfolio of innovative products designed to help Eye Care Professionals increase clinic and OR efficiency, and deliver exceptional patient experiences. The Alcon Vision Suite will continue to grow with cutting-edge Unity products that are expected to be introduced over the coming years, adding to our market-leading legacy products, which will continue to be available and serviceable. Unity VCS will be supported by Alcon's training, product maintenance, and Services teams.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.ca.
About UNITY VCS
Indications / Intended Use 3: The UNITY ® VCS (Vitreoretinal Cataract System) console, when used with compatible devices, is indicated for use during anterior segment (i.e. phacoemulsification and removal of cataracts) and posterior segment (i.e. vitreoretinal) ophthalmic surgery. In addition, with the optional laser, this system is indicated for photocoagulation (i.e. vitreoretinal and macular pathologies), iridotomy and trabeculoplasty procedures.
Please refer to the Directions for Use for the accessories/consumables and User Manual for a complete listing of indications, warnings, cautions and notes.
^2x faster nucleus removal than OZIL Torsional phaco
*Based on N=10 HPs, Artificial cataract lens IOP 55 mmHg vacuum of 450 mmHg
# Compared to Constellation HYPERVIT 20k vitrectomy probe
OZIL - Trademarks are the property of their respective owners.
References
Alcon Data on File, 2024 - REF-24379.
Alcon Data on File, 2024 - REF-24644.
Unity VCS User Manual 2024 – REF-24980.
Market Scope 2023 Retinal Surgical Device Market Report, 2023.
Market Scope 2023 Cataract Surgical Equipment Market Report, 2023.
Market Scope 2024 IOL Market Report, 2024.
CNIB – Blindness in Canada, Accessed December 2, 2024 - REF-19527.
The Prevalence of Canadian Vision Loss and Cataract Surgery, 2019 - REF-01661.
Conference Board of Canada - Ophthalmology in Canada: Why Vision Loss Should Not Be Overlooked, 2020 - REF-10834.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
11 minutes ago
- Globe and Mail
Top Analyst Reports for T-Mobile, AstraZeneca & Comcast
Tuesday, July 8, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), AstraZeneca PLC (AZN) and Comcast Corp. (CMCSA). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today's research reports here >>> Ahead of Wall Street The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning. You can read today's AWS here >>> Pre-Markets Mixed at Start of Prime Day, Awaiting Trade Deals Today's Featured Research Reports T-Mobile's shares have outperformed the Zacks Wireless National industry over the past year (+34.5% vs. +30.7%). The company is benefiting from industry-leading postpaid customer growth with a record-low churn rate. Its acquisition strategy has significantly strengthened its position in the wireless industry over the past few years. TMUS' 2.5 GHz 5G spectrum delivers superfast speeds and extensive coverage with signals that go through walls and trees. This boosts its competitive edge against companies that provide 5G networks controlled by the mmWave spectrum. However, owing to the stock's premium valuation, we believe investors should remain cautious as macroeconomic factors, market saturation, or economic downturns can significantly impact overvalued stocks like TMUS. Fierce competition is straining profitability. To lure customers from competitors, T-Mobile has launched several low-priced service plans for consumers. This has put pressure on profits. (You can read the full research report on T-Mobile here >>>) Shares of AstraZeneca have outperformed the Zacks Medical - Biomedical and Genetics industry over the year-to-date period (+7.7% vs. -2%). The company's key drugs like Lynparza, Tagrisso, Imfinzi and Fasenra should keep driving revenues. Its pipeline is strong, with pivotal late- and mid-stage pipeline data readouts lined up. AstraZeneca has also been engaged in external acquisitions and strategic collaborations to boost its pipeline. AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period. However, potentially lower sales of Lynparza and Farxiga in China, the impact of Part D redesign on U.S. oncology sales and slowing sales of rare disease drugs are expected to hurt the top line in 2025. Estimates have declined slightly ahead of the Q2 earnings release. The company has a mixed record of earnings surprises in recent quarters. (You can read the full research report on AstraZeneca here >>>) Comcast's shares have underperformed the Zacks Cable Television industry over the year-to-date period (-3.1% vs. +4.2%). The company has been persistently suffering from video-subscriber attrition due to cord-cutting. Broadband prospects are suffering from increased competition from fixed wireless and fiber businesses. Theme Parks revenues declined due to lower revenues at domestic theme parks, driven by lower guest attendance, including the impact of the Hollywood wildfires. A leveraged balance sheet is a major concern for Comcast. Nevertheless, steady growth in Content & Experiences revenues driven by steady performances by Studios and Media segments is positive. Its streaming service, Peacock, has been a key catalyst in driving broadband sales. Decreasing programming & production costs bode well for CMCSA's profitability. Strong free cash flow generation ability is noteworthy. (You can read the full research report on Comcast here >>>) Other noteworthy reports we are featuring today include Entergy Corp. (ETR), Align Technology, Inc. (ALGN) and Universal Health Services, Inc. (UHS). Mark Vickery Senior Editor Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read T-Mobile (TMUS) Rides on Solid 5G Expansion, Strong Cash Flow Key Drugs Aid AstraZeneca (AZN) Sales, Pipeline Strong Domestic Wireless Subscriber Gain Benefits Comcast (CMCSA) Featured Reports Investments Aid ETR Corporation (ETR) Amid Poor Solvency Per the Zacks analyst, ETR Corp. makes disciplined investment to maintain and upgrade the reliability of its electric utility systems. Yet its poor financial ratios indicate weak solvency position. Align (ALGN) Rides on Growing Invisalign Volume, Innovation The Zacks analyst is optimistic about Align's strong market rollout of several Invisalign products globally. The company's focused efforts to expand portfolio aids growth. Rising Admissions Aid Universal Health (UHS), High Costs Ail Per the Zacks analyst, Universal Health's continued growth in admissions at its acute care facilities will boost its top line. However, escalating expenses remain a concern for the company. Strong SMB clientele Aids BILL Holdings' (BILL) Prospects Per the Zacks analyst, BILL is benefiting from an expanding small and medium business (SMB) clientele, as well as a diversified business model. Expanding Customer Base & Smart Investment Aid ONE Gas (OGS) Per the Zacks analyst, ONE Gas is set to benefit from capital expenditure plan and extension of services to new areas. Steady demand from residential customers boosts its performance. Business Growth Plans Aid Boise Cascade (BCC), Macro Risks Ail Per the Zacks analyst, Boise Cascade is gaining from accretive business growth strategies, while ensuring shareholder value. However, housing market softness and macro risks hurt prospects. Sarepta (SRPT) Growth Outlook Dimmed by Elevidys Concerns Though Sarepta's pipeline of LGMD therapies holds potential, the Zacks analyst is concerned with two Elevidys-linked deaths and their impact on topline growth. New Upgrades Loan Growth & Strong Liquidity Supports SouthState (SSB) Per the Zacks analyst, SouthState's expanding loan balance and solid non-interest income will aid top-line growth. Its strong liquidity position enables sustainable capital distributions. SkyWest (SKYW) Benefits From Improving Air-Travel Demand The Zacks Analyst is impressed with the fact that increased air-travel demand is helping SkyWest carry more passengers and witness more revenues. TreeHouse Foods (THS) Drives Growth with Supply Chain Wins Per the Zacks analyst, TreeHouse Foods accelerates margin expansion with supply chain efficiencies, streamlined operations, and a focused portfolio in high-growth private label categories. New Downgrades Expected Decline in Sales & High Capex to Ail Magna (MGA) Per the Zacks analyst, Magna's 2025 revenues are expected to decline due to lower light vehicle production in North America. High capex requirement is likely to strain near-term cash flows. Trucking Costs & Oil Price Swings to Ail Vista Energy (VIST) Per the Zacks analyst, Vista Energy's heavy reliance on trucking for transporting production and its exposure to volatile international oil prices are expected to weigh on its profitability. Weak Digital Sales Hurts Bath & Body Works' (BBWI) Growth Per the Zacks analyst, despite favorable foot traffic, BBWI's digital softness in first quarter suggests cracks in its e-commerce strategy that could weigh on future performance. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Entergy Corporation (ETR): Free Stock Analysis Report Comcast Corporation (CMCSA): Free Stock Analysis Report Universal Health Services, Inc. (UHS): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report T-Mobile US, Inc. (TMUS): Free Stock Analysis Report
CTV News
21 minutes ago
- CTV News
Local companies team up to create entirely solar-powered ice cream shop
Bestie, the seasonal and sustainable shop from Kind Ice Cream, serving customers on Tuesday, July 8, 2025. (Miriam Valdes-Carletti/CTV News Edmonton) Locally made ice cream just got a whole lot greener thanks to two Edmonton companies that have found a way to pair the sweet treat with clean energy practices. Bestie is the new seasonal ice cream shop that will operate outside of Crestwood Community Hall this summer. Its parent shop is Kind Ice Cream – the women-led company born and raised in Edmonton. Kind Ice Cream originated in 2019 out of Ritchie from founders and owners Paula Shyba, Candace Morris and Nicole Bhar. Shyba said that when conceptualizing the new shop, kindness to the environment was at the top of their mind. 'We started exploring and considering if it was possible to even do solar [power] on a container like this,' she said. That's when they reached out to Grengine, a clean energy company based in Edmonton that specializes in renewable-powered systems like battery energy storage systems (BESS). Grengine designed the shop's system, which runs entirely off grid using solar panels and a battery system. Connie Stacey, CEO and founder of Grengine, said she was thrilled with being approached for an eco-friendly ice cream shop. She said it was the first time the company had done a commercial shop. 'It was really quite a fun project to do, to be honest. It just had a different, lighter feel,' Stacey said. Shyba told CTV News that the entire shop cost Kind Ice Cream in the range of $100,000. 'But it feels well worth it,' Shyba said. She noted that the shop did receive the Edmonton Edge Fund grant, which will help pay for another container shop in the likes of Bestie. Stacey said that they're still figuring out the exact number of solar panels needed for this particular container – currently, there are seven – but there's a backup generator in the event that any renewable sources fail. So while there is propane as a backup, Shyba said the goal is to be solar-powered for the entire summer, barring a large amount of bad weather. 'It is a system that will be able to keep our ice cream cold, knock on wood, so we feel pretty safe with our ice cream in there,' she said. Stacey said that Grengine is looking to collect more data about the panels over the summer to perfect the system. 'Melted ice cream is a whole lot of screaming kids,' she said. 'So this is definitely serious stuff.' With files from CTV News Edmonton's Miriam Valdes-Carletti
CTV News
22 minutes ago
- CTV News
Stanley Park Train won't return this year, and maybe never will
The beloved and beleaguered Stanley Park Train will remain closed for the rest of the year. The beloved and beleaguered Stanley Park Train will officially remain off the tracks for the rest of 2025 – meaning no Halloween or Christmas route – and the City of Vancouver is deliberating the future of the attraction. The 1960s-era locomotive was halted early last holiday season after a worker got sick from exhaust fumes, adding to a long list of reasons the attraction has operated only sporadically over the past five years, including mechanical problems, the pandemic, and coyotes. In a presentation to the Vancouver Board of Parks and Recreation Monday, staff said the train is at the end of its life, and therefore repairs are becoming more frequent and expensive. The Stanley Park Train lost $2.9 million from 2019 to 2024 and about $700,000 this year, according to the report. The situation as it stands poses safety, financial, reputational, and operational risks, the park board heard. Staff presented three possible options for the future of the site on Monday, which include electrifying and fixing the current train, replacing the train and its tracks, and creating a new attraction entirely with a third-party partner. 'Preliminary analysis shows that a full renewal of the train and the ancillary buildings and amenities could require substantial capital investment,' reads a Tuesday news release from the City of Vancouver. 'Alternative operating models, including some form of partnership or third-party operation could lead to a revitalized, reimagined attraction that would reduce the reliance on tax dollars to return the site to operation.' Fixing or replacing the train would cost about $8 million and would garner the lowest financial returns, staff told the board. Meanwhile, the report said the city has received 'multiple proposals' from businesses to build something new, and claimed that would lead to more revenue and more visitors, including tourists. Park Board Commissioner Scott Jensen told CTV News he'd most like to see the train remain in Stanley Park, but will keep an open mind and wants to hear what residents prefer. The presentation indicated ticket prices at an externally operated site could go up to $45. Staff anticipate an increase in prices if the attraction remains at the status quo as well, up to $20. 'I would want to look at what is going to be the best fit for that space that lets the most people have access to it, you know, some parks should not be for some and exclude others,' Jensen said. The specifics of keeping the train in action or remaking the site with a new business model remain up in the air. Consultation on the options is expected to begin this quarter and a call for expression of interest will launch later this year. Park board staff are expected to present further findings in early 2026. 'As part of their report, staff will bring forward proposed strategies for engaging key interest holders and the public, as appropriate, on any changes to the train and its site,' the city's statement reads.
